Pfizer Inc. (NYSE:PFE) Shares Bought by First National Bank of Mount Dora Trust Investment Services

First National Bank of Mount Dora Trust Investment Services lifted its position in Pfizer Inc. (NYSE:PFEGet Rating) by 0.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 132,530 shares of the biopharmaceutical company’s stock after acquiring an additional 773 shares during the quarter. Pfizer accounts for approximately 2.4% of First National Bank of Mount Dora Trust Investment Services’ holdings, making the stock its 9th largest position. First National Bank of Mount Dora Trust Investment Services’ holdings in Pfizer were worth $6,949,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Pfizer during the 4th quarter valued at approximately $3,351,891,000. Capital International Investors boosted its position in Pfizer by 3,059.6% during the 1st quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock valued at $1,994,698,000 after purchasing an additional 37,310,556 shares during the period. Vanguard Group Inc. boosted its position in Pfizer by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after purchasing an additional 13,790,348 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after acquiring an additional 10,440,786 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its position in Pfizer by 28.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after acquiring an additional 9,537,621 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Pfizer Stock Performance

PFE opened at $44.57 on Friday. The company has a market cap of $250.14 billion, a PE ratio of 8.72, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The stock has a 50-day moving average of $48.40 and a 200-day moving average of $50.33. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The business had revenue of $27.74 billion during the quarter, compared to analysts’ expectations of $26.20 billion. During the same quarter in the previous year, the firm earned $1.07 EPS. The firm’s revenue was up 46.8% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.59%. Pfizer’s dividend payout ratio is presently 31.31%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PFE. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research report on Tuesday, June 28th. Barclays set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. SVB Leerink reduced their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research report on Friday, July 29th. UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. Finally, Berenberg Bank set a $44.00 price target on Pfizer in a research report on Wednesday, September 14th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.